Vertex Pharmaceuticals Incorporated
VRTX
$388.33
-$6.79-1.72%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.16% | 8.88% | 11.66% | 10.06% | 8.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.46% | 8.98% | 11.66% | 10.06% | 8.76% |
| Cost of Revenue | 11.56% | -4.62% | -6.75% | -3.52% | -2.33% |
| Gross Profit | 9.79% | 19.95% | 26.63% | 20.57% | 16.87% |
| SG&A Expenses | 14.10% | 19.96% | 25.96% | 40.67% | 32.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.63% | 15.67% | 15.57% | 21.78% | 21.97% |
| Operating Income | 10.21% | 0.18% | 6.62% | -3.87% | -6.11% |
| Income Before Tax | 1,937.26% | -106.30% | -94.33% | -93.98% | -95.01% |
| Income Tax Expenses | 4.51% | -7.93% | 3.14% | -11.90% | -25.15% |
| Earnings from Continuing Operations | 842.52% | -124.60% | -114.80% | -113.83% | -114.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 842.52% | -124.60% | -114.80% | -113.83% | -114.56% |
| EBIT | 10.21% | 0.18% | 6.62% | -3.87% | -6.11% |
| EBITDA | 9.25% | 0.02% | 6.65% | -2.70% | -5.01% |
| EPS Basic | 847.05% | -124.45% | -114.72% | -113.76% | -114.46% |
| Normalized Basic EPS | 6.50% | -1.96% | 4.80% | -1.35% | -0.73% |
| EPS Diluted | 787.39% | -125.47% | -115.87% | -114.98% | -115.73% |
| Normalized Diluted EPS | 6.31% | -1.74% | 5.00% | -1.14% | -0.44% |
| Average Basic Shares Outstanding | -0.28% | -0.11% | 0.10% | 0.19% | 0.34% |
| Average Diluted Shares Outstanding | -0.08% | -0.37% | -0.14% | -0.05% | 0.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |